TUEBINGEN, Germany and HOUSTON, January 8, 2016 /PRNewswire/ --
Immatics Biotechnologies GmbH, a leading company in the field of cancer immunotherapy announces the appointment of Katina Dorton as Chief Financial Officer (CFO), effective immediately.
Katina brings more than 20 years' of experience in investment banking and has served as a senior strategic advisor to numerous companies in the life sciences, medical devices and healthcare sectors. She is a former Managing Director Investment Banking, Morgan Stanley in New York and Frankfurt, Germany, serving 12 years at the firm. She later was Managing Director, Life Sciences, at Needham & Co. Prior to her investment banking career Dorton practiced law in mergers and acquisitions at Sullivan & Cromwell.
Katina's has deep expertise in corporate finance, capital raising and M&A, having led the execution of over 60 completed financing transactions raising more than $50 billion in equity and debt, including 25 IPOs and advised on dozens of M&A transactions.
Katina holds BA in Economics from Duke University, an MBA from George Washington University and a JD from the University of Virginia.
Peter Chambré, Chairman of Immatics, said: "We are delighted to welcome Katina to Immatics as our new CFO. Katina's experience working with innovative life sciences companies and strong track record leading corporate transactions and managing financial operations makes her an excellent addition to the Immatics senior management team. I am confident her expertise will prove hugely valuable as we work to execute our strategy and advance our broad portfolio of advanced immunotherapies for the treatment of cancer."
Katina Dorton, Chief Financial Officer of Immatics, said: "I am thrilled to be joining Immatics with its unique target discovery technology and prospects in cancer immunotherapy. I look forward to helping the company grow and to achieve its goal of changing the course of the disease and saving the lives of cancer patients."
Immatics is a global leader in cancer immunotherapy. This leading position is based on Immatics' unique and world-leading target discovery platform XPRESIDENT® that enables the company to discover novel relevant, highly specific cancer antigens, both intra-cellular and surface, that are expressed by tumor cells for a range of cancer immunotherapies including adoptive cellular therapies, soluble T-cell receptors and antibodies. The antigens that XPRESIDENT® discovers have the major advantage to be confirmed to be naturally expressed in human cancer tissue - in contrast to targets identified by widely applied in silico and indirect techniques.
Immatics is developing three adoptive cellular therapy approaches in collaboration with the University of Texas MD Anderson Cancer Center: ACTolog™, ACTengine™ and ACTallo™, the first of which is expected to enter the clinic in 2016.
Immatics is also working on soluble T-cell receptor (TCR) approaches through its proprietary TCR discovery platform. In addition, through its partnerships with Roche and MorphoSys, Immatics is also developing novel antibody-based therapeutics against multiple proprietary cancer antigens recognized by T cells.
Immatics is based in Tuebingen, Germany and in Houston, Texas.
For additional information on Immatics please visit www.immatics.com or contact:
Citigate Dewe Rogerson
SOURCE Immatics Biotechnologies GmbH